홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

NIZA티딘

Nizatidine

HCID 4513
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
76963-41-2
표준 SMILES
CNC(=C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1
InChIKey
SGXXNSQHWDMGGP-UHFFFAOYSA-N
분자식
C12H21N5O2S2
평균 분자량
331.5 g/mol
단동위원소 질량
331.11366728

개요

A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.

이름 및 식별자

우선 이름
Nizatidine
IUPAC
1-N'-[2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
현지명
NIZA티딘
영어명
Nizatidine
분자식
C12H21N5O2S2
분자량
331.46

이름 및 동의어

AcinonNizatidinaAxidAxid ArNizatidinumDTXSID5023376P41PML4GHRLY 139037NSC-7592891,1-Ethenediamine, N-(2-(((2-((dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-LY-139037N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamin
이름 더 보기
NIZA티딘NIZA티딘(NIZATIDINE)nizaxze-101NizaxiZL-101gastraxnizaxidzanizalTizanon
N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamineCHEBI:7601DTXCID403376Zinga 150Zinga 300LY139037RefChem:55724A02BA04

데이터베이스 식별자

CAS
76963-41-2
PubChem CID
4513
DTXSID
DTXSID5023376
ChEMBL
CHEMBL3183075
UNII
P41PML4GHR
EC Number
627-310-4

물성

구조 계산 물성

XLogP
1.6
극성 표면적
140 Ų
수소 결합 공여자 수
2
수소 결합 수용자 수
8
회전 가능 결합 수
9
무거운 원자 수
21
형식 전하
0
복잡도
349

실험 및 물리화학적 성질

Chemical ClassesPharmaceutical
OdorMild, sulfur-like odor
TasteBitter
Color/Form · 2건

Crystals from ethanol-ethyl acetate

Off-white to buff crystalline solid

Solubility · 2건

10-33mg/mL

Soluble in water

Human Drugs · 3건

Breast Feeding; Lactation; Anti-Ulcer Agents; Histamine H2 Antagonists; Gastrointestinal Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point · 2건

130-132 °C

130-132 °C

Collision Cross Section178.1 Ų [M+Na]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID5023376]

물리화학적 성질

녹는점
130 · 130-1320C

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H302 (97.6%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 41 reports by companies from 2 notifications to the ECHA C&L Inventory.

유해성 정보

Other Safety InformationIMAP assessments - 1,1-Ethenediamine, N-[2-[[[2-[(dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N'-methyl-2-nitro-: Environment tier I assessment
FDA Requirements · 1건

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Hazard Classes and CategoriesAcute Tox. 4 (97.6%)

안전 및 보호

Disposal Methods · 1건

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

독성 정보

Interactions · 5건

Concurrent use /of antacids/ with histamine H2-receptor antagonists in the treatment of peptic ulcer may be indicated for the relief of pain; however, simultaneous administration of antacids of medium to high potency (80 mmol to 150 mmol HCl) is not recommended since absorption of histamine H2-receptor antagonists may be decreased; patients should be advised not to take any antacids within 1/2 to 1 hour of histamine H2-receptor antagonists. /Histamine H2-receptor antagonists/

화학 및 산업

약리 정보

ATC Code · 2건

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Protein Binding35%
Pharmacodynamics · 1건

Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells. By inhibiting the action of histamine on stomach cells, nizatidine reduces stomach acid production. Nizatidine had no demonstrable antiandrogenic action. Full-dose therapy for the problems treated by nizatidine lasts no longer than 8 weeks. It has been demonstrated that treatment with a reduced dose of nizatidine is effective as maintenance therapy following healing of active duodenal ulcers.

Mechanism of Action · 1건

Nizatidine competes with histamine for binding at the H<sub>2</sub>-receptors on the gastric basolateral membrane of parietal cells. Competitive inhibition results in reduction of basal and nocturnal gastric acid secretions. The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin.

Biological Half-Life · 2건

1-2 hours

Half life is 10 hours.

Metabolism/Metabolites · 2건

Hepatic. Less than 7% of an oral dose is metabolized as N2-monodes-methylnizatidine, an H2-receptor antagonist, which is the principal metabolite excreted in the urine. Other likely metabolites are the N2-oxide (less than 5% of the dose) and the S-oxide (less than 6% of the dose).

Nizatidine is metabolized in the liver to N-desmethylnizatidine, nizatidine N-oxide, and nizatidine sulfoxide. Of these metabolites, only N-desmethylnizatidine has histamine H2-receptor blocking activity; studies in animals indicate that this metabolite is approximately 60% as active as nizatidine in blocking gastric acid secretion. Orally administered nizatidine undergoes minimal metabolism on first pass through the liver.

FDA Pharmacological Classification

관련 반응

2건
반응 기록 만들기
HRID 279939 반응식
HRID 279939생성물로
HRID 1548466 반응식
HRID 1548466생성물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
끓는 점
478.2 · 478.2±45.0 °C(Predicted)
밀도
1.249 · 1.249±0.06 g/cm3(Predicted)
저장 조건
Keep in dark place,Inert atmosphere,Room temperature
용해도
물에 거의 용해되지 않으며 메탄올에 용해됩니다.
산도 계수 (pKa)
2.1 · 2.1, 6.8(at 25℃)
물리적 상태
Solid
색상
황백색에서 연한 노란색
수용성
21.4 g/L · 21.4g/L(온도 미표시)
Merck
14 · 14,6660
InChI
InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3
InChIKey
SGXXNSQHWDMGGP-UHFFFAOYSA-N
SMILES
C(NCCSCC1=CSC(CN(C)C)=N1)(NC)=C[N+]([O-])=O

화학적 성질

White Crystalline Powder

Concurrent use /of bone marrow depressants/ with H2-receptor antagonists may increase the risk of neutropenia or other blood dyscrasias. /Histamine H2-receptor antagonists/

Histamine H2-receptor antagonists may increase gastrointestinal pH; concurrent administration of ketoconazole with histamine H2-receptor antagonists may result in a marked reduction in absorption of ketoconazole; patients should be advised to take histamine H2-receptor antagonists at least 2 hours after ketoconazole. /Histamine H2-receptor antagonists/

Although a decrease in absorption is only reported in the literature for cimetidine and ranitidine, concurrent use with sucralfate may decrease the absorption of any H2-receptor antagonist; patients should be advised to take an H2-receptor antagonist 2 hours before sucralfate. /Histamine H2-receptor antagonists/

No drug interactions were reported when nizatidine and theophylline, lidocaine, warfarin, chlordiazepoxide, diazepam, or lorazepam were used together.

Hepatotoxicity · 1건

Chronic therapy with nizatidine and other H2 blockers is associated with minor elevations in serum aminotransferase levels in 1% to 4% of patients, but similar rates have been reported in placebo recipients. The ALT elevations are usually asymptomatic and transient and may resolve without dose modification. Rare instances of clinically apparent liver injury have been reported in patients receiving nizatidine, but too few cases have been reported to characterize a typical time to onset or pattern of injury. More information is available on the hepatotoxicity of other H2 blockers such as ranitidine and cimetidine which have been implicated in causing clinically apparent liver injury in 1:20,000 to 1:100,000 users. The time to onset of H2 blocker induced liver injury tends to be short, between 1 and 6 weeks of starting. The typical pattern of serum enzyme elevations varies from hepatocellular to cholestatic, most cases being “mixed”. The injury can be severe, but is typically mild-to- moderate in severity and self-limited in course, resolving within 4 to 12 weeks of stopping. Immunoallergic features (rash, fever, eosinophilia) are uncommon, as is autoantibody formation. Liver biopsy histology often shows centrolobular (zone 3) necrosis with mixed cellular infiltrates and mild cholestasis.

Human Toxicity ExcerptsNizatidine may inhibit alcohol dehydrogenase in the gastric mucosa and produce higher serum levels of alcohol, but this does not appear to be clinically significant.
Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Nizatidine

vLess-DILI-concern

5

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Non-Human Toxicity Excerpts · 5건

Studies in rats and mice with oral doses many times the recommended human dose showed no evidence of carcinogenicity.

Studies in rats and rabbits with oral doses up to 300 and 55 times the human dose, respectively, have not shown that nizatidine impairs fertility.

Rabbits treated with a dose equivalent to 300 times the human dose had abortions, a decreased number of live fetuses, and depressed fetal weights.

Nizatidine is distributed into milk in rats, and growth depression has occurred in the offspring of lactating rats treated with the drug.

For more Non-Human Toxicity Excerpts (Complete) data for NIZATIDINE (9 total), please visit the HSDB record page.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
USGS Health-Based Screening Levels for Evaluating Water-Quality · 3건

Nizatidine

Pharmaceutical

Smith, C.D. and Nowell, L.H., 2024. Health-Based Screening Levels for evaluating water-quality data (3rd ed.). DOI:10.5066/F71C1TWP

EPA Human Health Benchmarks for Pharmaceuticals · 6건

Nizatidine

3.5

14.8

The recommended oral dosage for adults is 150 mg once daily at bedtime.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 150 mg/day, Lowest Therapeutic Dose (LTD): 1.9 mg/kg-day, and Screening Dose: 0.0006 mg/kg-day.

31-Mar-16

규제 정보

FDA Requirements · 1건

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

안전 데이터

wgk
3
rtecs
KM6565000
독성
LD50 in mice, rats (mg/kg): 265, >300 i.v.; 1685, 1680 orally (Pioch)
HS 번호
2934999090
risk_code
22
hazard_code
Xn
safety_code
36
기존화학 물질
KE-11160
Hazard Classifications
Acute Tox. 4 Oral
스토리지 클래스
11 - Combustible Solids
유해 물질 데이터
76963-41-2(Hazardous Substances Data)
· 6건

P41PML4GHR

NIZATIDINE

Mechanisms of Action [MoA] - Histamine H2 Receptor Antagonists

Established Pharmacologic Class [EPC] - Histamine-2 Receptor Antagonist

Nizatidine is a Histamine-2 Receptor Antagonist. The mechanism of action of nizatidine is as a Histamine H2 Receptor Antagonist.

NIZATIDINE

MeSH Pharmacological Classification · 2건

Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief.

Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood.

Absorption, Distribution and Excretion · 6건

Rapid (bioavailability of nizatidine exceeds 70%)

0.8 to 1.5 L/kg

40-60 L/h

Nizatidine has a duration of action of up to 10 hours. It is eliminated primarily by the kidneys; 90% of the administered dose (65% as unchanged drug) is recovered in the urine within 16 hours.

Distribution of nizatidine into human body tissues and fluids has not been fully characterized. The apparent volume of distribution of the drug is reported to be 0.8-1.5 l/kg in adults and does not appear to be altered substantially in patients with renal dysfunction.

In one study, the oral bioavailability of nizatidine exceeded 70% and was not affected by food or the anticholinergic drug, propantheline. Its apparent volume of distribution is 1.2 l/kg. Systemic clearance (10 ml/min/kg) is decreased in uremic patients and in the elderly.

용도 및 제조

UsesMEDICATION
Methods of ManufacturingRP Pioch, Eur Pat Appl 49618; Idem, US Pat 4,375547 (1982, 1983 both to Eli Lilly)
Formulations/PreparationsEach Pulvule (capsule) contains for oral administration gelatin, pregelatinized starch, silicone, titanium dioxide, yellow iron oxide and 150 mg or 300 mg nizatidine.
응용 분야 · 3건

개요Nizatidine is the fifth H2-antagonist introduced to the world market as an antiulcer agent. It is reported to be effective in the treatment of both duodenal and gastric ulcers or the prevention of their recurrences. Given once-daily, nizatidine’s bioavailability is not diminished by the concurrent administration of an antacid.

용도Nizatidine is used for treating stomach and duodenum ulcers and other conditions accompanied by elevated acidity of the gastrointestinal tract.

일반 설명Nizatidine, N-[2-[[[2-(dimethylamino)methyl]-4-thiazolyl]methyl]thio]-ethyl]-N'-methyl-2-nitro-1,1-ethenediamine (Axid), is an off-white to buff crystallinesolid that is soluble in water, alcohol, and chloroform. It isa thaizole derivative of raniditine and has pKas of 2.1 (side chain) and 6.8 (dimethylamino). Nizatidine’s mechanism ofaction is similar to other H2-antagonists, as is its receptor selectivity.It is more potent than cimetidine.Nizatidine has excellent oral bioavailability (>90%).The effects of antacids or food on its bioavailability arenot clinically significant. The elimination half-life is 1 to2 hours. It is excreted primarily in the urine (90%) andmostly as unchanged drug (60%). Metabolites include nizatidinesulfoxide (6%), N-desmethylnizatidine (7%), andnizatidine N-oxide (dimethylaminomethyl function).Nizatidine has no demonstrable antiandrogenic action, effectson other hormones, or inhibitory effects on cytochromeisozymes involved in the metabolism of other drugs.

상·하류 제품 정보

상류 원료

황화 수소DimethylamineE에틸렌디아민나이트로메테인비스 (클로로메틸) 케톤2-Dimethylaminomethyl-4-Chloromethyl-4-hydrony thiazolineThiazolidine크리소이딘Dimethyl aminothic acetamide1-비닐피렌Dimethyl amino acetenitrile초산에틸2-디메틸아미노메틸-4-클로로메틸티아졸HCL메틸알콜Anhydrous pyridine사이클로헥사논1,1-Bis(methylthio)-2-nitroethylene요오드 메탄사이안화 칼륨아세트알데히드암모니아메틸아민2-니트로메틸레네티아졸리딘

추가 설명

정의ChEBI: A member of the class of 1,3-thiazoles having a dimethylaminomethyl substituent at position 2 and an alkylthiomethyl moiety at position 4.